ADMA Biologics (ADMA) PT Raised to $16 at Oppenheimer Amid Asceniv Approval
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell raised the price target on ADMA Biologics (NASDAQ: ADMA) to $16.00 (from $14.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
